Blood & Marrow Transplant Clinical Account Manager

Omeros faces European narsoplimab setback after re-examination. A negative European opinion leaves Omeros facing regulatory uncertainty over narsoplimab in TA-TMA, with the basis and next steps still unclear. Key facts. * Regulatory outcome: CHMP issued a negative opinion following re-examination of the European marketing authorization application. * Medicine and indication: Narsoplimab in TA-TMA. * Most recent share close: OMER: 16.20, currency and exchange unspecified in the supplied data; down 13.78%; last trade October 16, 2026, at 20:00 GMT. * Outstanding information: The supplied facts do not identify the committee's detailed rationale or Omeros's next regulatory steps. Omeros Corporation received a negative CHMP opinion after re-examination of its European marketing authorization application for narsoplimab in TA-TMA, while its shares closed down 13.78%. Omeros Corporation received a negative opinion from the Committee for Medicinal Products for Human Use, or CHMP, following re-examination of its European marketing authorization application for narsoplimab in TA-TMA. The outcome leaves the company without a favorable committee recommendation from that review and puts the regulatory path, rather than commercial execution, at the center of the European investment case. Omeros shares, identified in the supplied market data as OMER, finished down 13.78% at the most recent close on October 16, 2026. That decline accompanied the regulatory setback, although the available information does not establish how much of the move was attributable to the opinion rather than other influences. The immediate distinction is important: the confirmed event is a negative scientific committee opinion following re-examination. It should not be described as a newly announced withdrawal, a termination of development or a confirmed final decision on every possible European route for the medicine. Re-examination did not produce a favorable opinion. Omeros confirmed the outcome for narsoplimab in TA-TMA in the announcement carried by Business Wire. The verified information establishes the result, but does not supply the committee's detailed reasoning or a company timetable for responding. A re-examination is consequential because it gives an applicant's case another regulatory assessment. Here, that process did not deliver a positive opinion. For investors, the practical implication is that a favorable recommendation cannot be treated as the immediate foundation for a European launch forecast. That is narrower than saying the medicine has no clinical value. A regulatory assessment concerns whether an application supports authorization for a proposed use. Without the reasoning behind this opinion, it is not possible to identify whether the decisive issue involved the strength of the efficacy evidence, safety, the design of the supporting studies or another aspect of the application. Those possibilities should not be confused with reported findings. No specific deficiency is established by the supplied facts. The negative outcome is clear; the precise evidentiary hurdle Omeros would need to address is not. The missing rationale determines the next investment question. The most useful next disclosure would explain why the committee remained negative after re-examination. A concern that could be addressed through additional analysis has different implications from a requirement for new clinical evidence. Neither route can be assumed from the outcome alone. That distinction matters for both development spending and timing. Further analysis and a new study can involve very different commitments of money, staff and patients. Until the required work is identified, attaching a budget or a revised authorization date would create precision that the available information does not support. Omeros's response also matters. The company could clarify how it interprets the opinion, whether it intends to pursue further regulatory engagement and what evidence it believes would be needed. These are questions to monitor, not actions established by the announcement available here. The company could clarify how it interprets the opinion, whether it intends to pursue further regulatory engagement and what evidence it believes would be needed. Investors should distinguish a stated intention to continue from an executable regulatory plan. A plan becomes more informative when it identifies the outstanding questions, the work proposed to answer them and the process through which regulators would assess the response. General confidence in a drug does not resolve those practical requirements. Patient access and commercial planning remain separate hurdles. TA-TMA refers to transplant-associated thrombotic microangiopathy. For patients and clinicians following narsoplimab's European application, the negative opinion means this review has not produced the favorable recommendation they may have been awaiting. It does not, by itself, establish what treatment options or other access arrangements are available to an individual patient. Authorization and access are also different questions. Even a favorable authorization outcome would not automatically answer every question about prescribing, reimbursement or availability. With the committee opinion negative, however, the immediate issue remains the application's regulatory standing rather than the details of a routine commercial rollout. For commercial planning, the disciplined approach is to avoid treating prospective European sales as assured. Any estimate would depend on an authorization pathway, an eventual permitted use and the conditions under which the medicine could reach patients. None of those commercial assumptions can be quantified from the supplied announcement. The same caution applies to the rest of Omeros's business. This event concerns the European application for narsoplimab in TA-TMA. It does not establish the status of applications elsewhere, outcomes in other indications or changes to unrelated programs. Extending the result beyond its stated scope would overstate the news. The share decline shows pressure, not a financial forecast. The 13.78% decline in Omeros shares was larger than the supplied broad-market benchmark declines at the same close. The S&P 500 benchmark was down 1.11%, while the Nasdaq 100 benchmark fell 2.50%. That comparison places the stock's weakness in context without proving a precise cause for the selling. A share-price reaction is not a calculation of the company's eventual financial loss. The available information does not quantify European revenue expectations, additional development costs or the effect on cash needs. It therefore cannot support a revised valuation or a conclusion about financing requirements. The next substantive milestone is clarity: the committee's reasoning, the company's response and any confirmed procedural steps. Until those emerge, the defensible reading is a significant European regulatory setback with unresolved consequences - not a dated recovery plan, an assumed launch delay or a quantified verdict on narsoplimab's future. Frequently asked questions. What happened to Omeros's European narsoplimab application? Omeros received a negative opinion from the Committee for Medicinal Products for Human Use following re-examination of its European marketing authorization application for narsoplimab in TA-TMA. The confirmed outcome is an unfavorable committee opinion. The supplied information does not establish a subsequent final authorization decision or a company response timetable. Why did the CHMP issue a negative opinion? The verified information supplied for this report does not identify the committee's detailed reasoning. It would therefore be speculative to attribute the outcome to efficacy, safety, study design or another particular deficiency. The rationale is important because it determines what evidence or regulatory work might be needed to address the concerns. How did Omeros shares perform at the latest close? Omeros shares, identified as OMER in the supplied market data, closed down 13.78%, with the last trade recorded on October 16, 2026, at 20:00 GMT. The market was closed at that point. The data did not identify the listing exchange or currency, so neither should be inferred. Does the opinion mean narsoplimab development has ended? The negative CHMP opinion does not, by itself, establish that Omeros has ended development of narsoplimab. The confirmed event concerns the European application for TA-TMA after re-examination. No termination decision, further development plan or timetable was included in the verified facts supplied for this report. What should investors watch for next? Investors should watch for the committee's detailed rationale and Omeros's stated response. Useful disclosures would identify outstanding evidence requirements, proposed work and confirmed regulatory procedures. Without those details, estimates of additional spending, an authorization timetable or prospective European sales would depend on assumptions rather than the verified announcement. What does the outcome mean for patients? The review has not produced a favorable CHMP recommendation for narsoplimab in TA-TMA. That is a regulatory setback, but it does not establish an individual patient's treatment options or access arrangements. The supplied information also does not describe changes to existing care, alternative therapies or access outside this application.

Stock market today: S&P 500, Nasdaq rise as softer inflation data lifts rate outlook. 3 hours ago 44 5 minutes read U.S. stocks edged higher on Thursday as another encouraging inflation report helped ease fears of a near-term Federal Reserve rate hike, while investors worked through a busy round of corporate earnings. The S&P 500 gained about 0.5%, while the tech-heavy Nasdaq Composite advanced roughly 0.7% as growth stocks benefited from a friendlier rate backdrop. The Dow Jones Industrial Average bucked the trend, slipping about 0.1% as the blue-chip index struggled for direction. Thursday's gains followed Wednesday's cooler consumer inflation report, with softer producer prices adding to evidence that inflation pressures may be stabilizing despite continued uncertainty surrounding energy markets and the Strait of Hormuz. Market movers: * Omeros (OMER) +29% - Shares surged after the biotech company delivered better-than-expected second-quarter results as the commercial rollout of YARTEMLEA gained momentum, with gross revenue from the drug reaching $32.2 million, up 190% from the first quarter. Omeros also swung to adjusted net income of $1.8 million from a $17.1 million adjusted loss in Q1 and ended the quarter with $132 million in cash and short-term investments. * Birkenstock (BIRK) +13% - Shares jumped after the footwear company posted stronger-than-expected fiscal third-quarter results, with revenue climbing 13% year over year to €719.5 million as direct-to-consumer and wholesale sales both posted double-digit growth. Investors welcomed the company's ability to maintain full-price demand despite pressure on discretionary spending, although tariffs, currency headwinds and Middle East tensions remain potential drags on margins. * IREN (IREN) +11% - Shares rallied after the AI infrastructure company completed and received acceptance for its first AI Cloud deployment for Microsoft under their $9.7 billion, five-year cloud services agreement. The 50-megawatt Horizon 1 deployment is now operational at IREN's Childress, Texas campus, while the company continues targeting 480 megawatts of gross AI Cloud capacity in 2026 and 1.2 gigawatts in 2027. * Microsoft (MSFT) +2% - Shares rose after JPMorgan lifted its price target on the software giant to $625 from $550 while maintaining an Overweight rating, citing accelerating opportunities across Copilot and AI infrastructure. The firm sees AI spending supporting faster Azure and Microsoft 365 Commercial Cloud growth, with Copilot potentially adding between $24 billion and $41 billion in revenue. * Cerebras Systems (CBRS) -10% - Shares plunged after the AI chipmaker delivered weaker-than-expected second-quarter revenue and a steep adjusted earnings miss despite continued rapid growth in its core business. Revenue climbed 74.3% year over year to $180.1 million but fell short of consensus, while management projected full-year core revenue of $880 million to $890 million. * Cisco Systems (CSCO) -7% - Shares fell despite the networking giant beating fiscal fourth-quarter expectations and delivering guidance above Wall Street forecasts, highlighting how demanding expectations have become for companies tied to the AI infrastructure boom. Revenue increased 18% year over year to $17.3 billion, while Cisco expects roughly $7.5 billion in AI-related hyperscaler revenue in fiscal 2027 after hyperscaler orders more than doubled in the latest quarter. * Virgin Galactic (SPCE) -5% - Shares dropped after the space tourism company pushed the beginning of commercial service to February 2027 from the fourth quarter of 2026 as it works through additional avionics and systems installations. Virgin Galactic said demand remains strong and its $750,000 ticket tranche is oversubscribed, but the latest delay extends the wait for meaningful commercial revenue. * JD.com (JD) -4% - Shares declined after the Chinese e-commerce company reported better-than-expected quarterly results but showed signs of softer top-line momentum, with product revenue falling 5.4%. Service revenue grew 6.8% and profitability improved significantly, but cautious consumer spending, intensifying competition and a 10.4% increase in fulfillment expenses kept investors focused on the challenges ahead. Softer inflation data gives the Fed more breathing room. Thursday's Producer Price Index added to evidence that inflation pressures are beginning to cool. Producer prices rose less than economists had expected, while core measures showed slower price growth on both a monthly and annual basis. The report followed Wednesday's Consumer Price Index, which showed annual inflation easing to 3.4% in July from 3.5% in June. Together, the reports have encouraged investors to scale back expectations for a September rate hike, particularly after July's surprisingly weak employment report showed the U.S. economy losing 23,000 jobs. That does not mean the inflation fight is over. Price growth remains well above the Federal Reserve's 2% target, leaving policymakers with an uncomfortable mix of softer employment and still-elevated inflation. The question increasingly facing markets is whether recent moderation will prove durable enough for the Fed to remain on hold through the rest of the year. Oil and the Strait of Hormuz remain a wild card. Energy prices remain one of the biggest threats to that improving inflation picture. Oil prices moved lower Thursday as the Trump administration shifted its focus from active military operations toward economic pressure on Iran, but uncertainty surrounding shipping through the Strait of Hormuz remains elevated. The disruption matters well beyond energy markets. A prolonged restriction on oil shipments could push crude prices higher again, feed through to transportation and production costs, and complicate the Fed's efforts to bring inflation under control. The dollar is also caught between competing forces. Reduced expectations for Fed tightening could pressure the currency, while continued geopolitical instability and the United States' position as a major energy producer could preserve demand for the dollar as a safe-haven asset. AI earnings put sky-high expectations to the test. Earnings season continues to reveal a striking divide in the AI trade: demand for computing infrastructure remains enormous, but investors are becoming increasingly selective about which companies receive credit for that growth. Cisco's decline despite better-than-expected results offered another example. Its AI-related hyperscaler business continues to expand rapidly, yet strong numbers were not enough to satisfy investors after a powerful run for AI infrastructure stocks. Cerebras faced an even harsher reaction after its revenue and earnings fell short of expectations. At the same time, IREN's Microsoft deployment reinforced the scale of spending still flowing into the sector. Investors will get another important read after Thursday's close when chip-equipment heavyweight Applied Materials reports results, with its outlook likely to provide another window into semiconductor demand and the durability of the AI infrastructure cycle. Looking ahead. Markets now have two encouraging inflation reports in hand, giving investors more reason to believe the Federal Reserve can remain patient after July's weak jobs data. If inflation continues to cool without a deeper deterioration in employment, the prospect of an extended Fed pause could provide support for equities, particularly rate-sensitive technology and growth stocks. But the path remains unusually dependent on developments outside the traditional economic calendar. Oil prices, the Strait of Hormuz, elevated Treasury yields, and increasingly demanding expectations for AI companies all have the potential to quickly shift sentiment. With major indexes hovering near record territory, investors will be looking for confirmation that cooling inflation and resilient corporate growth can keep the rally moving without another shock upsetting the balance.